TNF-alpha levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.

To investigate TNF-alpha levels in children with GH deficiency (GHD), to evaluate alteration in TNF-alpha levels during recombinant human GH (rhGH) treatment, and to analyze possible correlations between TNF-alpha and GH, IGF-1 and IGFBP-3.

Who Took Part

PubMed indexes the participants as children and teenagers, both men and women.

In children with GHD, blood samples were drawn before (TNF-alpha0), and at 6 (TNF-alpha6) and 12 (TNF-alpha12) months of the treatment with rhGH.

How the Study Was Run

Eleven had complete and 13 had partial GHD.

Age and sex distribution, body mass indexes of two groups were similar.

TNF-alpha was determined using a human TNF-alpha ELISA assay (Biosource International).

What Was Measured

The subject headings attached to it are Growth Hormone, Hormone Replacement Therapy, Human Growth Hormone, Hypopituitarism and Tumor Necrosis Factor-alpha.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.